Monrovia, CA, January 24, 2009 --(PR.com
)-- Sue Richards, Ph.D., Group Vice President of Clinical Laboratory Sciences at Genzyme Corporation in Framingham, MA will give the keynote address entitled “Immunogenicity of Protein Therapeutics: Strategies and Implications.” at GTCbio’s 3rd annual Immunodiagnostics & Immunomonitoring Conference on April 23-24, 2009 in Chicago, IL.
Dr. Richards will provide the attendees with an overview of immunogenicity of recombinant human therapeutic proteins. She will explain risk-based assessment and provide a strategy for immunomonitoring. She will also provide analytical approaches to assess immunogenicity and clinical consequences of anti-drug antibodies.
Dr. Richards has been at Genzyme for twenty years and is responsible for directing and supervising the Immunology and Clinical Laboratory Science Departments. Dr. Richards worked for E.I. Dupont de Nemours & Co. for five years in the Medical Products Division prior to joining Genzyme. Dr. Richards received her Ph.D. in Microbiology from SUNY at Buffalo, and completed a postdoctoral fellowship at the Wadsworth Center for Laboratories and Research in Albany, NY in the Vaccinia Virus Vaccine Program.
Dr. Richards’ presentation, along with over 25 other distinguished speakers, can be heard by attending the 3rd Annual Immunodiagnostics & Immunomonitoring Conference on April 23-24, 2009 in Chicago, IL. The conference will cover novel approaches & methods for immunodiagnostics, evaluation of innovative immunodiagnostic techniques, immunomonitoring of clinical trials, innovative techniques for future clinical use, and biomarkers in immunodiagnostics & immunomonitoring. For more information visit http://gtcbio.com/conferenceDetails.aspx?id=147.